生长激素释放肽-2 GHRP-2

GHRP-2 is one of the most potent synthetic growth hormone secretagogues ever studied — a six-amino-acid peptide that tells your pituitary gland to release a pulse of growth hormone by mimicking ghrelin, the body's own "hunger hormone." That's a meaningful distinction from GHRH-based peptides: GHRP-2 works through an entirely different receptor, which is why researchers have long been interested in combining the two approaches.

In Japan, it's been approved under the name Pralmorelin as a diagnostic agent for growth hormone deficiency testing.^[1] In the United States, GHRP-2 carries no FDA approval and is classified for research purposes only. It's not available through compounding pharmacies or by prescription for therapeutic use in the US.

Despite that status, GHRP-2 has shown up in nutritional supplements and black-market injection products — a pattern that reflects both genuine interest in its GH-releasing effects and the risks that come with unregulated sourcing.^[2][3]

Key Takeaways

• GHRP-2 stimulates growth hormone release by binding the ghrelin receptor (GHS-R1a) — a completely different pathway than GHRH-based peptides like CJC-1295.

It's approved in Japan as a diagnostic agent (Pralmorelin) but carries no FDA approval in the US, where it is research-use only.

WADA prohibits GHRP-2 in competitive sports; it has been detected in black-market supplements and seized injection vials.

The most clinically relevant side effect beyond GH elevation is a meaningful increase in appetite — a direct consequence of ghrelin receptor activation.

Long-term human safety data in healthy adults is sparse; most published evidence comes from short-duration studies or diagnostic protocols.

Class	Growth Hormone Secretagogue (GHS)
Amino Acids	6 (hexapeptide)
Mechanism	GHS-R1a (ghrelin receptor) agonism → Gq/PLC/calcium signaling → GH pulse
FDA Status	Research Only — not FDA-approved
Approved (Japan)	Pralmorelin — diagnostic use (GH deficiency testing)
Administration	Subcutaneous or intravenous injection (research use)
Typical Research Dose	1–2 mcg/kg subcutaneously — dosing in humans has not been established; animal and preliminary clinical data exist but specific dosing ranges are not verified from available sources
WADA Status	Prohibited — all GHRPs banned in sport
Primary Research Uses	GH regulation, endocrine research, receptor biology
Evidence Level	Preclinical / early clinical (no Phase 3 RCTs in the US)

The key to understanding GHRP-2 is understanding what it's binding to. Most people assume growth hormone secretagogues all work the same way — they don't. GHRP-2 targets the ghrelin receptor, formally called GHS-R1a, which is distinct from the GHRH receptor that peptides like CJC-1295 activate.^[4] That distinction matters because the two pathways are additive: hit both at once and you get a larger GH pulse than either alone can produce.

When GHRP-2 binds GHS-R1a, it activates a Gq protein, which triggers phospholipase C (PLC) and ultimately causes a spike in intracellular calcium inside pituitary somatotroph cells.^[4] That calcium surge is what drives the release of stored growth hormone. The whole process happens quickly — GH levels typically peak within 15–30 minutes of injection, though the time to peak GH levels following GHRP-2 administration has not been established in published human clinical data — and the pulse is transient, mimicking the body's natural episodic GH secretion pattern rather than producing a sustained flat elevation.

This pulsatile release is actually considered an advantage over exogenous recombinant human growth hormone (rhGH). Continuous supraphysiologic GH exposure blunts the pituitary's own regulatory feedback. Secretagogues like GHRP-2 work within the body's existing feedback architecture — if GH levels are already high, the response is blunted naturally.^[5] That self-limiting quality is part of why researchers view GH secretagogues as potentially safer than direct GH administration, though long-term human data to confirm that hypothesis remains limited.

One thing you can't separate from GHRP-2's mechanism: it's activating the same receptor that ghrelin activates, and ghrelin is a potent appetite stimulant. Increased hunger is not an incidental side effect — it's a direct pharmacological consequence of what GHRP-2 does.

There are no published Phase 3 randomized controlled trials establishing an official therapeutic dose for GHRP-2 in the United States. The ranges below reflect what has appeared in published human research studies and diagnostic protocols.

Not clinical dosing guidance

GHRP-2 is not FDA-approved for therapeutic use in the US. The doses described here come from research protocols and the Japanese diagnostic approval, not from US clinical trials. Dosing should only be discussed with a licensed healthcare provider familiar with this compound.

In published human research, GHRP-2 has been studied at doses ranging from approximately 1 mcg/kg to 2 mcg/kg administered subcutaneously or intravenously.^[1][5] For a 75 kg adult, that translates to roughly 75–150 mcg per injection — though dosing in humans has not been established; reported ranges in research literature vary and require full-text review to verify. The Japanese Pralmorelin diagnostic protocol uses a single intravenous dose of 100 mcg to stimulate a GH pulse for deficiency testing.^[1]

In practitioner-reported protocols outside clinical trials, GHRP-2 is often used at fixed doses of 100–300 mcg per injection, administered subcutaneously two to three times daily — typically on an empty stomach to maximize GH response, since elevated blood glucose blunts GH secretion. GHRP-2 dosing and administration routes have not been established in human clinical trials; reported ranges are based on early-phase research and are not approved for human use. These practitioner ranges are not derived from randomized trials and should be treated accordingly.

100 mcg single IV dose used in Japanese Pralmorelin diagnostic protocol for GH deficiency testing

When GHRP-2 is combined with a GHRH analogue like CJC-1295 or Sermorelin, the GH pulse is substantially larger than with either peptide alone — a synergy that has been explored in research settings, though efficacy claims and synergistic mechanisms in humans remain to be established, and is the basis for most combination protocols used in practice.

Among the synthetic GHRPs, GHRP-2 sits at the high end of potency. It may produce a stronger GH pulse than GHRP-6 at equivalent doses — though GHRP-2 and GHRP-6 have not been directly compared in published human clinical trials, so comparative potency claims cannot be verified from available literature — and unlike GHRP-6, it causes a smaller increase in prolactin and cortisol relative to its GH-releasing effect — a ratio that researchers have noted as clinically relevant.^[5]

The dual-pathway synergy

GHRP-2 activates the ghrelin receptor (GHS-R1a). GHRH-based peptides like CJC-1295 activate the GHRH receptor. Because these are separate receptor systems with separate intracellular signaling cascades, combining them produces a GH pulse that's meaningfully larger than either compound alone. Most practitioner protocols that use GHRP-2 therapeutically do so in combination with a GHRH analogue for exactly this reason.

The ghrelin receptor angle also gives GHRP-2 a profile that extends beyond pure GH release. Ghrelin itself has documented effects on appetite, gastric motility, and energy balance. GHRP-2, as a GHS-R1a agonist, shares some of those downstream effects — which is both a feature (for patients trying to increase caloric intake and lean mass) and a liability (for anyone who doesn't want to be significantly hungrier).

Most of the published human data on GHRP-2 comes from two contexts: short-term GH stimulation studies in healthy volunteers or GH-deficient patients, and the Japanese diagnostic approval for Pralmorelin.

The Pralmorelin diagnostic application is the most clinically validated use. A single 100 mcg intravenous dose reliably produces a measurable GH pulse, making it useful for distinguishing true GH deficiency from normal pituitary function.^[1] This is the only approved indication anywhere in the world.

In research settings, GHRP-2 has consistently demonstrated dose-dependent GH release in healthy adults, with the GH response blunted by hyperglycemia and augmented by co-administration of GHRH.^[5] Studies examining the cortisol and prolactin co-secretion — which occurs with most GHRPs — have found that GHRP-2 produces these elevations, though the clinical significance in short-term use remains debated.^[5]

The receptor biology has been well characterized. A key 1998 study confirmed that GHRP-2 does not act through the GHRH receptor, settling an earlier question about its mechanism and establishing that its effects are GHS-R1a-mediated — a finding that underpins the rationale for combination protocols.^[4]

What the Evidence Does Not Show

• Long-term safety in healthy adults — Published studies are short-duration, typically days to weeks. There are no multi-year safety datasets for GHRP-2 in non-deficient adults using it for body composition or anti-aging purposes.
• Body composition outcomes from RCTs — The GH elevation is well-documented. Whether that translates to meaningful, sustained changes in lean mass or fat mass in humans hasn't been established in controlled trials.
• Cardiovascular outcomes — No long-term cardiovascular safety data exists. The concern with sustained GH elevation — including potential effects on insulin sensitivity and IGF-1 levels — hasn't been systematically studied for GHRP-2 specifically.
• Optimal dosing frequency and duration — Research protocols vary widely. There's no established consensus on how often to dose, for how long, or whether pulsatile versus continuous approaches produce meaningfully different outcomes.
• Head-to-head comparisons with other GHRPs — Direct comparative trials between GHRP-2, GHRP-6, Ipamorelin, and other secretagogues in humans are sparse. Cross-study comparisons exist but are methodologically unreliable.

Consistent across use:

• Increased appetite — This isn't a rare side effect. It's a direct consequence of GHS-R1a activation, the same receptor ghrelin uses to signal hunger. Most people notice it within 30–60 minutes of injection. For someone trying to increase caloric intake, it's useful. For someone who isn't, it's a real problem.
• Transient cortisol and prolactin elevation — GHRP-2 co-stimulates cortisol and prolactin release alongside GH.^[5] In short-term research studies, these elevations are transient. The clinical significance of repeated elevations over weeks or months isn't well characterized.
• Water retention — Elevated GH and IGF-1 promote sodium and water retention. Mild edema, particularly in the hands and feet, is commonly reported. Edema has been reported in some clinical contexts, but frequency and severity in humans have not been formally established.

Injection-related:

• Injection site reactions — Redness, mild swelling, and tenderness at the injection site are reported, particularly with subcutaneous administration. Rotating sites reduces this.
• Transient lightheadedness — Some users report a brief drop in blood pressure or lightheadedness shortly after injection, likely related to the acute GH pulse; however, transient lightheadedness or blood pressure changes have not been established as documented adverse effects in available clinical data for GHRP-2, and any such reports remain anecdotal and unverified in published human trials.

Worth monitoring:

• Insulin sensitivity — Chronic GH elevation can impair insulin sensitivity. People with prediabetes or metabolic syndrome should be particularly cautious, and fasting glucose and HbA1c (a 90-day average of blood sugar levels) should be monitored with any extended use.

If you notice persistent edema, significant changes in fasting glucose, or breast tissue changes (which can occur with sustained prolactin elevation), those are specific reasons to stop use and speak with a physician — not after a few more weeks, immediately.

US regulatory status — research use only

GHRP-2 is not FDA-approved for any therapeutic indication in the United States. It is not available by prescription through licensed compounding pharmacies for patient use. In the US, it is legal to purchase for legitimate laboratory research purposes only — not for human administration. In Japan, it is approved as Pralmorelin for diagnostic use only, not as a therapeutic agent.

WADA's Prohibited List bans all growth hormone releasing peptides, including GHRP-2, in competitive sport.^[2] Detection methods have been developed and validated — GHRP-2 has been identified in seized injection vials and in nutritional supplements sold without disclosure of pharmaceutical ingredients.^[2][3]

The FDA has taken enforcement action against companies marketing unapproved peptide products for human use. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity.

Because GHRP-2 has no legal commercial pathway for human therapeutic use in the US, any product marketed for injection in humans falls outside the regulatory framework. That includes products sold through gray-market research chemical vendors.

If you're researching GHRP-2 for legitimate laboratory purposes, the same quality concerns that apply to any research peptide apply here — perhaps more so, given that GHRP-2 has been found adulterated or mislabeled in seized products.^[2][3]

What to look for:

• Third-party Certificate of Analysis (COA) — The testing lab should be independent from the vendor. Ask for the lab's name and look it up. In-house testing is not a substitute.
• HPLC purity report — Look for ≥98% purity by high-performance liquid chromatography. Mass spectrometry confirmation of the correct molecular weight is a meaningful additional marker of authenticity.
• Sequence verification — Given that novel GHRP-2 analogues (including glycine-substituted variants) have been found in seized products,^[2] sequence confirmation matters if the research application requires a specific compound.

Red flags:

• No COA or vendor-only testing — The most common marker of a low-quality supplier. Walk away.
• Price significantly below market — Peptide synthesis and independent testing have real costs. A price that seems too good to be true usually reflects corners cut somewhere in the process.
• Marketed explicitly for human injection — Research chemical vendors are not permitted to sell GHRP-2 for human use. Any vendor making explicit therapeutic claims is operating outside legal bounds and is a sourcing risk.

GH Secretagogues: How GHRP-2 Compares

Parameter	GHRP-2	Ipamorelin	Sermorelin
Receptor target	GHS-R1a (ghrelin)	GHS-R1a (ghrelin)	GHRH receptor
GH pulse potency	High	Moderate	Moderate
Cortisol/prolactin elevation	Yes — notable	Minimal	Minimal
Appetite stimulation	Significant	Mild	None
FDA status (US)	Research only	Research only	Research only
WADA prohibited	Yes	Yes	Yes — not established in humans

Ipamorelin is often described as a more selective alternative to GHRP-2 — it hits the same ghrelin receptor but produces significantly less cortisol and prolactin co-secretion, and the appetite stimulation is milder. The tradeoff is that Ipamorelin's GH pulse is generally considered less potent than GHRP-2's at equivalent doses, though comparative potency between Ipamorelin and GHRP-2 at equivalent doses has not been established in human clinical trials. For researchers prioritizing a clean GH signal with fewer confounding hormonal effects, Ipamorelin is the more commonly used option in current practice.

Sermorelin works through an entirely different receptor (the GHRH receptor) and has no appetite or cortisol effects. It's often combined with a GHRP like GHRP-2 or Ipamorelin to leverage the dual-pathway synergy described above. See our GHRP-2 vs. Ipamorelin comparison for a more detailed breakdown of the practical differences.